In comparison to valsartan (an angiotensin II receptor blocker), sacubitril–valsartan (a molecule combining angiotensin receptor blocking agent and neprilysin inhibitor) did not achieve a substantial decrease in CV-related mortality or HF hospitalization in individuals with HF and an EF ≥ 45% who were enrolled in the PARAGON-HF trial [348]. Here, MME is linked to hydrops fetalis.